| Bioactivity | Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a therapeutic humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer[1]. |
| Invitro | Farletuzumab (MORAb-003; 0-10 µg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1].Farletuzumab (0.1-100 µg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro[1].Farletuzumab (0-10 µg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | Farletuzumab |
| CAS | 896723-44-7 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ebel W, et, al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007 Mar 9;7:6. |